环孢素A治疗特应性皮炎的疗效观察

Therapeutic effect of cyclosporine A in treatment of atopic dermatitis

目的评价环孢素A治疗特应性皮炎的疗效和安全性。方法选取2016年1月—2018年12月中南大学湘雅医学院附属海口医院皮肤科收治的64例特应性皮炎患者,随机分为治疗组和对照组,每组32例。对照组口服依巴斯汀片20 mg/d联合医用凡士林外用;治疗组口服环孢素A 3 mg/(kg·d)联合医用凡士林外用。采用酶联免疫吸附试验检测血清总免疫球蛋白E(TIgE)水平;比较两组患者在治疗后第4周、第8周的临床总有效率、SCORAD积分、TIgE水平;比较两组患者的不良反应,评价其疗效及安全性。结果治疗后第4周,治疗组SCORAD积分低于对照组(P<0.05),治疗组血清TIgE低于对照组(P<0.05)。治疗后第8周,治疗组有效率高于对照组(P<0.05),治疗组的SCORAD积分低于对照组(P<0.05),治疗组血清TIgE低于对照组(P<0.05)。结论环孢素A治疗特应性皮炎的有效率优于依巴斯汀。环孢素A能迅速控制病情,3 mg/(kg·d)的使用剂量用药安全,不良反应少。

Objective To investigate the clinical effect and safety of cyclosporine A in the treatment of patients with atopic dermatitis.Methods A total of 64 patients were randomly divided into two groups,each of 32 cases.The control group was treated with ebastine tablet 20 mg once daily and vaseline for external use.The treatment group was treated with cyclosporine A 3 mg/kg once daily and vaseline for external use.The two groups patients were treated for 8 weeks.The clinical curative effect and SCORAD scores and total IgE value in serum in 4th and 8th week were observed.All the adverse reactions were recorded.Results After 4 weeks of treatment,the SCORAD score of the treatment group was significantly lower than that of the control group(P<0.05).The serum TIgE of the treatment group was significantly lower than that of the control group(P<0.05).The above differences were statistically significant(P<0.05).After 8 weeks of treatment,the effective rate of the treatment group was significantly higher than that of the control group(P<0.05).The SCORAD score of the treatment group was significantly lower than that of the control group(P<0.05).The serum TIgE of the treatment group was significantly lower than that of the control group(P<0.05).Conclusion The effect of cyclosporine A is better than ebastine in the treatment of patients with atopic dermatitis.The disease was quickly controlled with cyclosporine A.Less adverse reactions and more safety with cyclosporine A 3 mg/kg once daily occurred in the research.